Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
The MMSE and AD8 are fundamentally different cognitive screening tools, though they’re often confused because both help identify dementia risk. The MMSE is a 30-point performance-based test that directly measures cognitive abilities—memory, attention, language, and basic spatial reasoning—while the AD8 is an 8-point informant-based questionnaire that relies on a family member or caregiver to report whether they’ve noticed changes in a person’s thinking and behavior. In practical terms, the MMSE asks “what can this person do right now?” while the AD8 asks “have you noticed a change in how they function?” For example, an elderly woman might score well on an MMSE during a clinical visit because she’s focused and in a controlled environment, but her daughter might report on the AD8 that Mom is forgetting conversations and getting lost in familiar places—changes the daughter has witnessed over months.
These tests also serve different clinical purposes. The MMSE provides detailed information about which cognitive domains are affected and the severity of impairment using a specific numerical scale. The AD8, by contrast, is designed as a rapid screening tool to identify whether someone should be referred for further evaluation. Understanding these differences is crucial because choosing the wrong test for your situation can lead to missed diagnoses, unnecessary additional testing, or false reassurance.
Table of Contents
- What Are the Key Structural Differences Between MMSE and AD8?
- How Do the Clinical Cutoff Scores Work for Dementia Detection?
- Why Informant-Based Screening Changes Everything
- Which Test Should You Use and When?
- What Happens When You Use Both Tests Together?
- Understanding What the Tests Actually Miss
- How These Tests Inform Care Planning and Next Steps
- Conclusion
What Are the Key Structural Differences Between MMSE and AD8?
The mmse produces a score from 0 to 30, with lower scores indicating greater cognitive impairment, and typically takes less than ten minutes to administer. During the test, a healthcare provider directly observes and evaluates a person’s orientation to time and place, immediate and delayed memory recall, attention span, the ability to name objects, understanding of verbal and written commands, sentence writing ability, and the ability to copy a simple drawing. This direct observation creates an objective snapshot of cognitive function at a single moment in time. The AD8, by contrast, produces a score from 0 to 8, with each item scored as either 1 (indicating the person has noticed a change) or 0 (indicating no change has been noticed).
Rather than directly testing the person, the AD8 asks an informant—typically a family member, spouse, or long-term caregiver—eight questions about whether they’ve observed decline in memory, decision-making, navigation, financial management, medication management, mood or behavior, ability to handle complex tasks, and repeating questions or stories. This makes the AD8 a behavioral observation tool rather than a performance assessment. The practical implication is important: the MMSE can be administered by a healthcare provider in a clinical setting to anyone, but requires cognitive capacity to engage with the testing items. The AD8 doesn’t require the person being evaluated to participate at all—it relies entirely on the observations of someone who knows them well, which is both an advantage and a potential limitation depending on circumstances.

How Do the Clinical Cutoff Scores Work for Dementia Detection?
For the MMSE, a cutoff score of 21 has demonstrated 77.78% sensitivity and 73.58% specificity for detecting dementia, according to recent 2024 research. This means that if someone scores 21 or below on the MMSE, there’s a fairly strong likelihood they have cognitive impairment, though some people without dementia will also fall below this threshold. Clinicians must interpret MMSE scores within the context of a person’s education level, age, and cultural background, as these factors influence performance independent of cognitive disease. The AD8 uses variable cutoff thresholds depending on the clinical goal.
A cutoff of ≥2 is used to distinguish between normal cognition and mild cognitive decline, while a cutoff of ≥3 includes more severe cases. A cutoff of ≥4 optimizes the balance between sensitivity and specificity—what researchers call the Youden index—for detecting dementia specifically. The informant-based version of the AD8 (called iAD8) shows 91% sensitivity and 64% specificity for dementia when using a cutoff of ≥2, meaning it catches most people with dementia but may falsely flag some people without dementia. The critical limitation here is what researchers call the “specificity problem” with the AD8: while it rarely misses dementia, it tends to overidentify risk because caregivers are more likely to report changes if they’re worried, particularly in the early stages when changes are subtle and could reflect normal aging. This is why the AD8 is best used as a screening tool to identify who needs further testing, not as a definitive diagnosis on its own.
Why Informant-Based Screening Changes Everything
The AD8’s reliance on caregiver observations represents a fundamentally different approach to cognitive assessment. Research consistently shows that informant-based reports are more sensitive to subtle cognitive decline than self-assessment, particularly in early stages of dementia. A person in the early stages of mild cognitive impairment may underestimate their own difficulties due to lack of awareness (what neurologists call anosognosia), but a family member who interacts with them regularly will notice when they start repeating questions, struggling with bills, or getting confused about appointments. Consider a real-world scenario: a 72-year-old man takes an MMSE during an annual physical and scores 27, which is considered normal. His wife, however, reports on the AD8 that she’s noticed her husband forgetting recent conversations, struggling with their finances in a way he never did before, and asking the same questions multiple times per week.
The wife’s observations may be picking up early changes that don’t yet register as significant impairment on the MMSE. This is why the AD8 is often more effective at catching early cognitive decline—it’s measuring real-world functional changes rather than performance on a structured task. However, this strength also creates vulnerabilities. If the informant is unreliable, inattentive, or has their own cognitive or memory issues, the AD8 score loses validity. Additionally, cultural differences in how families perceive and report cognitive changes can affect the accuracy of the assessment. For someone living alone without regular contact with family, the AD8 may not be feasible at all.

Which Test Should You Use and When?
The MMSE is better suited for detailed cognitive evaluation when you need to understand which specific domains are impaired and measure the severity of cognitive changes over time. It’s the better choice for people who are already showing signs of cognitive impairment, for tracking progression over multiple visits, or for research studies that need objective quantifiable data. If your goal is to establish a baseline of cognitive function or to document decline in specific areas like memory versus language, the MMSE provides that granular information. The AD8 is designed for rapid initial screening in primary care settings, community screenings, or situations where you want a quick indicator of whether someone should be referred for further evaluation.
It’s particularly valuable for people showing subtle changes that family members have noticed but that might not yet show up on detailed cognitive testing. The AD8 requires minimal time, requires no special training to administer, and can be given even when a person is unwilling or unable to participate in formal cognitive testing. For caregivers concerned about early decline, the AD8 provides a quick, validated way to quantify those concerns. The tradeoff is straightforward: the MMSE gives you detailed information but takes longer and requires active participation; the AD8 gives you a quick signal but with less specificity and more reliance on the reliability of the informant. Neither test should be used in isolation for diagnosis—both are screening or assessment tools that should be part of a comprehensive evaluation including medical history, physical examination, and possibly neuroimaging or other specialized testing.
What Happens When You Use Both Tests Together?
Recent 2024 research demonstrates that using both the MMSE and AD8 in parallel produces superior results compared to either test alone. When both tests were used with an MMSE cutoff score of 21, the combination achieved 88.89% sensitivity and 70.16% specificity for detecting dementia. This is notably better sensitivity than either test individually—the MMSE alone shows 77.78% sensitivity, and the AD8 alone shows 91% sensitivity but with poor specificity that leads to overdiagnosis. By using both tests together, clinicians can cross-check their findings. If an MMSE score is low and the AD8 score is high, there’s strong concordant evidence of cognitive impairment.
If the tests disagree—for instance, if the MMSE score is normal but the AD8 score is elevated—it signals that the person may have subtle functional decline not yet captured by objective testing, or that the AD8 informant may be unreliable. This disagreement pattern becomes clinically useful information. One important limitation is that combining tests requires more time and resources. The MMSE takes less than ten minutes, but adding the AD8 and interpreting results together requires coordination between the clinic, the patient, and potentially an informant who may need to complete the questionnaire separately. In busy primary care settings, this dual approach isn’t always practical, which is why the AD8 alone is often used for initial screening.

Understanding What the Tests Actually Miss
The MMSE has important blind spots that clinicians must understand. While it effectively measures memory, orientation, and basic language abilities, it doesn’t adequately assess executive function (planning, problem-solving, decision-making) or visuospatial abilities beyond simple figure copying. This means a person with early dementia that primarily affects executive function might score deceptively well on the MMSE despite significant real-world functional decline. For example, someone with primary progressive dementia affecting language and executive skills might score 25 on the MMSE but be unable to manage medications or make financial decisions.
The AD8 doesn’t measure cognitive abilities directly, so it can’t distinguish between different types of cognitive impairment. An informant reporting behavioral changes might be describing dementia, depression, medication side effects, delirium from infection, or even normal aging. The AD8 flags that something has changed, but it doesn’t identify what or why. This is why both tests need to be embedded in a full clinical evaluation that includes detailed history, physical examination, and appropriate testing.
How These Tests Inform Care Planning and Next Steps
Understanding which test identifies what type of change helps guide what comes next in the diagnostic journey. A person who scores elevated on the AD8 but shows only subtle changes on MMSE often needs to be followed more closely with repeat testing in three to six months to document whether changes are progressing or stable. This kind of early detection allows for earlier intervention and family planning, even before a full dementia diagnosis can be made.
As cognitive assessment tools continue to evolve, the combination of standardized objective testing (like the MMSE) with informant-based functional assessment (like the AD8) remains the gold standard for initial evaluation. Neither test is perfect, but together they capture both the measurable cognitive changes and the real-world functional impact that matters most to people and their families. The future of cognitive screening likely involves using these validated tools together with additional assessments of specific domains and biomarkers, creating a more complete picture of brain health.
Conclusion
The fundamental difference between the MMSE and AD8 is that the MMSE directly measures what someone can do cognitively right now, while the AD8 measures changes that others have noticed over time. The MMSE provides a detailed score that tracks objective cognitive performance, while the AD8 provides a quick screening signal based on informant observations. Both serve important purposes, but they answer different questions and work best when used together as part of a comprehensive cognitive evaluation.
If you’re concerned about cognitive changes in yourself or a loved one, understanding these differences helps you advocate for appropriate testing. Neither test should be used in isolation for diagnosis, and neither can replace a thorough evaluation by a healthcare provider. What matters is recognizing early signs of change, getting appropriately evaluated, and beginning supportive care and planning as early as possible. Whether you start with an AD8 for quick screening or an MMSE for detailed assessment depends on your specific situation, but having both perspectives—objective performance and informant-reported changes—gives you the most complete picture.
You Might Also Like
- MMSE Score vs SLUMS Test: What Families Should Know
- MMSE Score vs Mini-Cog: Which Test Is Better?
- MMSE Score and Vision Problems
For more, see Alzheimer’s Association — medical tests.



